Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial: In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA):

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperConference abstract in journalResearchpeer-review

We present a clinical open label, phase-1 trial (OptimalTTF-1, NCT02893137), which aims to test a novel treatment for first recurrence glioblastoma (rGBM). The aim of the treatment is to optimize the electric field generated by Tumor Treating Fields (TTFields) with targeted and individualized skull-remodeling surgery (SR-surgery). Selectively placed burrholes reduces the electric resistance created by the bone and thus improves the electric field focally. Preclinical research has indicated this conclusion. The final analysis examined the toxicity and efficacy of this combined intervention in addition to best practice chemotherapy.
Original languageEnglish
Article numberCT103
JournalCancer Research
Volume80
Issue16, suppl.
ISSN0008-5472
DOIs
Publication statusPublished - 2020
EventAACR Annual Meeting 2020 - Philadelphia, United States
Duration: 27 Apr 202028 Apr 2020

Conference

ConferenceAACR Annual Meeting 2020
CountryUnited States
CityPhiladelphia
Period27/04/202028/04/2020

See relations at Aarhus University Citationformats

ID: 195927358